Effect of chronic kidney disease on platelet reactivity to dual-antiplatelet therapy in patients treated with drug-eluting stents

Takahide Arai, Akio Kawamura, Yumiko Matsubara, Kenji Yokoyama, Yasuo Ikeda, Keiichi Fukuda, Mitsuru Murata

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

We investigated the effect of chronic kidney disease (CKD) on platelet function in patients receiving dual-antiplatelet therapy after drug-eluting stent (DES) implantation. We examined 19 patients with CKD and 18 patients without CKD who underwent percutaneous coronary intervention (PCI) with DES. All of the patients had been on chronic aspirin treatment. Blood samples were obtained 20-24 h after a loading dose (300 mg) of clopidogrel. Platelet function was evaluated by measuring the closure time (CT) of a collagen/epinephrine (CEPI) or collagen/adenosine diphosphate (CADP) cartridge in the PFA-100 system. Maximum aggregation of agonist (epinephrine, ADP, collagen, or ristocetin)-induced platelet aggregation was also examined by light transmittance aggregometry. The frequency of the poor responders among CKD (n = 9, 47.4%) patients was significantly higher than that among non-CKD patients (n = 2, 11.1%, P = 0.016) as assessed using a CEPI-CT cartridge. Multiple logistic regression analysis revealed that CKD (odds ratio 7.39, 95% confidence interval 1.38-62.09, P = 0.0183] was the only independent determinant of the poor responders. There were no significant differences between the two groups in the value of CADP-CT or in maximum aggregation of epinephrine-, ADP-, collagen-, and ristocetininduced platelet aggregation. Compared with non-CKD patients, CKD patients had lower response to aspirin therapy as assessed by the PFA-100 system with a CEPI cartridge. On the other hand, the platelet response to dualantiplatelet therapy was not different between CKD and non-CKD patients.

Original languageEnglish
Pages (from-to)480-485
Number of pages6
JournalHeart and Vessels
Volume27
Issue number5
DOIs
Publication statusPublished - 2012 Sep

Fingerprint

Drug-Eluting Stents
Chronic Renal Insufficiency
Blood Platelets
Collagen
Epinephrine
Adenosine Diphosphate
Kidney Diseases
Therapeutics
clopidogrel
Platelet Aggregation
Aspirin
Ristocetin
Percutaneous Coronary Intervention
Logistic Models
Odds Ratio
Regression Analysis
Confidence Intervals
Light

Keywords

  • Dual-antiplatelet therapy
  • Light transmittance aggregometry
  • PFA-100 analyzer
  • Platelets

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Effect of chronic kidney disease on platelet reactivity to dual-antiplatelet therapy in patients treated with drug-eluting stents. / Arai, Takahide; Kawamura, Akio; Matsubara, Yumiko; Yokoyama, Kenji; Ikeda, Yasuo; Fukuda, Keiichi; Murata, Mitsuru.

In: Heart and Vessels, Vol. 27, No. 5, 09.2012, p. 480-485.

Research output: Contribution to journalArticle

Arai, Takahide ; Kawamura, Akio ; Matsubara, Yumiko ; Yokoyama, Kenji ; Ikeda, Yasuo ; Fukuda, Keiichi ; Murata, Mitsuru. / Effect of chronic kidney disease on platelet reactivity to dual-antiplatelet therapy in patients treated with drug-eluting stents. In: Heart and Vessels. 2012 ; Vol. 27, No. 5. pp. 480-485.
@article{40b0ad9fd63a4bceabb4b8456fafb220,
title = "Effect of chronic kidney disease on platelet reactivity to dual-antiplatelet therapy in patients treated with drug-eluting stents",
abstract = "We investigated the effect of chronic kidney disease (CKD) on platelet function in patients receiving dual-antiplatelet therapy after drug-eluting stent (DES) implantation. We examined 19 patients with CKD and 18 patients without CKD who underwent percutaneous coronary intervention (PCI) with DES. All of the patients had been on chronic aspirin treatment. Blood samples were obtained 20-24 h after a loading dose (300 mg) of clopidogrel. Platelet function was evaluated by measuring the closure time (CT) of a collagen/epinephrine (CEPI) or collagen/adenosine diphosphate (CADP) cartridge in the PFA-100 system. Maximum aggregation of agonist (epinephrine, ADP, collagen, or ristocetin)-induced platelet aggregation was also examined by light transmittance aggregometry. The frequency of the poor responders among CKD (n = 9, 47.4{\%}) patients was significantly higher than that among non-CKD patients (n = 2, 11.1{\%}, P = 0.016) as assessed using a CEPI-CT cartridge. Multiple logistic regression analysis revealed that CKD (odds ratio 7.39, 95{\%} confidence interval 1.38-62.09, P = 0.0183] was the only independent determinant of the poor responders. There were no significant differences between the two groups in the value of CADP-CT or in maximum aggregation of epinephrine-, ADP-, collagen-, and ristocetininduced platelet aggregation. Compared with non-CKD patients, CKD patients had lower response to aspirin therapy as assessed by the PFA-100 system with a CEPI cartridge. On the other hand, the platelet response to dualantiplatelet therapy was not different between CKD and non-CKD patients.",
keywords = "Dual-antiplatelet therapy, Light transmittance aggregometry, PFA-100 analyzer, Platelets",
author = "Takahide Arai and Akio Kawamura and Yumiko Matsubara and Kenji Yokoyama and Yasuo Ikeda and Keiichi Fukuda and Mitsuru Murata",
year = "2012",
month = "9",
doi = "10.1007/s00380-011-0180-y",
language = "English",
volume = "27",
pages = "480--485",
journal = "Heart and Vessels",
issn = "0910-8327",
publisher = "Springer Japan",
number = "5",

}

TY - JOUR

T1 - Effect of chronic kidney disease on platelet reactivity to dual-antiplatelet therapy in patients treated with drug-eluting stents

AU - Arai, Takahide

AU - Kawamura, Akio

AU - Matsubara, Yumiko

AU - Yokoyama, Kenji

AU - Ikeda, Yasuo

AU - Fukuda, Keiichi

AU - Murata, Mitsuru

PY - 2012/9

Y1 - 2012/9

N2 - We investigated the effect of chronic kidney disease (CKD) on platelet function in patients receiving dual-antiplatelet therapy after drug-eluting stent (DES) implantation. We examined 19 patients with CKD and 18 patients without CKD who underwent percutaneous coronary intervention (PCI) with DES. All of the patients had been on chronic aspirin treatment. Blood samples were obtained 20-24 h after a loading dose (300 mg) of clopidogrel. Platelet function was evaluated by measuring the closure time (CT) of a collagen/epinephrine (CEPI) or collagen/adenosine diphosphate (CADP) cartridge in the PFA-100 system. Maximum aggregation of agonist (epinephrine, ADP, collagen, or ristocetin)-induced platelet aggregation was also examined by light transmittance aggregometry. The frequency of the poor responders among CKD (n = 9, 47.4%) patients was significantly higher than that among non-CKD patients (n = 2, 11.1%, P = 0.016) as assessed using a CEPI-CT cartridge. Multiple logistic regression analysis revealed that CKD (odds ratio 7.39, 95% confidence interval 1.38-62.09, P = 0.0183] was the only independent determinant of the poor responders. There were no significant differences between the two groups in the value of CADP-CT or in maximum aggregation of epinephrine-, ADP-, collagen-, and ristocetininduced platelet aggregation. Compared with non-CKD patients, CKD patients had lower response to aspirin therapy as assessed by the PFA-100 system with a CEPI cartridge. On the other hand, the platelet response to dualantiplatelet therapy was not different between CKD and non-CKD patients.

AB - We investigated the effect of chronic kidney disease (CKD) on platelet function in patients receiving dual-antiplatelet therapy after drug-eluting stent (DES) implantation. We examined 19 patients with CKD and 18 patients without CKD who underwent percutaneous coronary intervention (PCI) with DES. All of the patients had been on chronic aspirin treatment. Blood samples were obtained 20-24 h after a loading dose (300 mg) of clopidogrel. Platelet function was evaluated by measuring the closure time (CT) of a collagen/epinephrine (CEPI) or collagen/adenosine diphosphate (CADP) cartridge in the PFA-100 system. Maximum aggregation of agonist (epinephrine, ADP, collagen, or ristocetin)-induced platelet aggregation was also examined by light transmittance aggregometry. The frequency of the poor responders among CKD (n = 9, 47.4%) patients was significantly higher than that among non-CKD patients (n = 2, 11.1%, P = 0.016) as assessed using a CEPI-CT cartridge. Multiple logistic regression analysis revealed that CKD (odds ratio 7.39, 95% confidence interval 1.38-62.09, P = 0.0183] was the only independent determinant of the poor responders. There were no significant differences between the two groups in the value of CADP-CT or in maximum aggregation of epinephrine-, ADP-, collagen-, and ristocetininduced platelet aggregation. Compared with non-CKD patients, CKD patients had lower response to aspirin therapy as assessed by the PFA-100 system with a CEPI cartridge. On the other hand, the platelet response to dualantiplatelet therapy was not different between CKD and non-CKD patients.

KW - Dual-antiplatelet therapy

KW - Light transmittance aggregometry

KW - PFA-100 analyzer

KW - Platelets

UR - http://www.scopus.com/inward/record.url?scp=84866734145&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866734145&partnerID=8YFLogxK

U2 - 10.1007/s00380-011-0180-y

DO - 10.1007/s00380-011-0180-y

M3 - Article

VL - 27

SP - 480

EP - 485

JO - Heart and Vessels

JF - Heart and Vessels

SN - 0910-8327

IS - 5

ER -